Sarepta Therapeutics Inc SRPT shares are trading higher by $3.24 (18 percent) at $21.24 in Monday's session. The catalyst for the rally is a letter circulating from Group of DMD doctors regarding the main drug in its pipeline, Eteplirsen.
After a higher open, it retreated only a dime to $18.15 before continuing its move higher. So far, it has reached $21.40 and is not far off that level. This marks the highest level for the issue since its swooned from it January 14 close ($31.630 to $14.28) the next day following efficacy concerns related to Eteplirsen.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
